Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 2;73(9):e3120-e3123.
doi: 10.1093/cid/ciaa1804.

Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey

Kristina L Bajema  1 , F Scott Dahlgren  1 , Travis W Lim  1 , Nicolette Bestul  1 , Holly M Biggs  1 , Jacqueline E Tate  1 , Claudio Owusu  1 , Christine M Szablewski  1   2 , Cherie Drenzek  2 , Jan Drobeniuc  1 , Vera Semenova  1 , Han Li  1 , Peter Browning  1 , Rita Desai  1 , Monica Epperson  1 , Lily T Jia  1 , Natalie J Thornburg  1 , Chris Edens  1 , Alicia M Fry  1 , Aron J Hall  1 , Jarad Schiffer  1 , Fiona P Havers  1
Affiliations

Comparison of Estimated Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Through Commercial Laboratory Residual Sera Testing and a Community Survey

Kristina L Bajema et al. Clin Infect Dis. .

Abstract

We compared severe acute respiratory syndrome coronavirus 2 seroprevalence estimated from commercial laboratory residual sera and a community household survey in metropolitan Atlanta during April and May 2020 and found these 2 estimates to be similar (4.94% vs 3.18%). Compared with more representative surveys, commercial sera can provide an approximate measure of seroprevalence.

Keywords: convenience sampling; coronavirus disease 2019 (COVID-19); seroprevalence; severe acute respiratory syndrome–related coronavirus 2 (SARS-CoV-2).

PubMed Disclaimer

Comment in

Publication types

Substances

Grants and funding